A photo of Michael Jordan.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Member, Division of Immunobiology

Professor, UC Department of Pediatrics

513-636-1773

513-803-1969

Board Certified

My Biography & Research

Clinical Interests

Histiocytic disorders: HLH and LCH

Research Interests

Better understanding histiocytic disorders and developing novel therapies for them; regulation of the immune response; immunotherapy of cancer

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, Leukemia, Hemophagocytic lymphohistiocytosisHLH, Histiocytosis Center, Autoimmune Liver Disease

Research Divisions

Bone Marrow Transplantation, Cancer and Blood Diseases, Immunobiology



Blog Posts

NEJM: Emapalumab Clinical Trial Shows Positive Results Against HLH

Rare Diseases

NEJM: Emapalumab Clinical Trial Shows Positive Results Against HLH

Michael B. Jordan, MD5/7/2020

Breakthrough Therapy Improves Life for Children with LRBA Deficiency

Rare Diseases

Breakthrough Therapy Improves Life for Children with LRBA Deficiency

Michael B. Jordan, MD6/28/2019

My Education

MD: UT Southwestern, Dallas, TX, 1993.

Residency: Children's Hospital of Dallas, Dallas, TX, 1996.

Fellowship: The Children's Hospital, Denver, CO, 2002.

Certification: American Board of Pediatrics, 1996; Sub-board of Pediatric Heme/Onc, 2002.

My Publications

Emapalumab in Primary Hemophagocytic Lymphohistiocytosis. Reply. Jordan, MB; Locatelli, F. The New England journal of medicine. 2020; 383:598-599.

CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Khandelwal, P; Fukuda, T; Teusink-Cross, A; Kashuba, AD M; Lane, A; Mehta, PA; Marsh, RA; Jordan, MB; Grimley, MS; Myers, KC; et al. Bone Marrow Transplantation. 2020; 55:1552-1559.

Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). Lee, PY; Kellner, ES; Huang, Y; Furutani, E; Huang, Z; Bainter, W; Alosaimi, MF; Stafstrom, K; Platt, CD; Stauber, T; et al. Journal of Allergy and Clinical Immunology. 2020; 145:1664-1672.e10.

Emapalumab in children with primary hemophagocytic lymphohistiocytosis. Locatelli, F; Jordan, MB; Allen, C; Cesaro, S; Rizzari, C; Rao, A; Degar, B; Garrington, TP; Sevilla, J; Putti, M; et al. The New England journal of medicine. 2020; 382:1811-1822.

mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection. Castro-Rojas, CM; Godarova, A; Shi, T; Hummel, SA; Shields, A; Tremblay, S; Alloway, RR; Jordan, MB; Woodle, ES; Hildeman, DA. Transplantation. 2020; 104:1058-1069.

Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Chan, AY; Leiding, JW; Liu, X; Logan, BR; Burroughs, LM; Allenspach, EJ; Skoda-Smith, S; Uzel, G; Notarangelo, LD; Slatter, M; et al. Frontiers in Immunology. 2020; 11.

The Variable Genomic NK Cell Receptor Locus Is a Key Determinant of CD4+ T Cell Responses During Viral Infection. Raynor, J; Lin, A; Hummel, SA; Lampe, K; Jordan, M; Hoebe, K; Hildeman, DA. Frontiers in Immunology. 2020; 11.

CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Khandelwal, P; Chaturvedi, V; Owsley, E; Lane, A; Heyenbruch, D; Lutzko, CM; Leemhuis, T; Grimley, MS; Nelson, AS; Davies, SM; et al. Biology of Blood and Marrow Transplantation. 2020; 26:1-6.

Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Jordan, MB; Allen, CE; Greenberg, J; Henry, M; Hermiston, ML; Kumar, A; Hines, M; Eckstein, O; Ladisch, S; Nichols, KE; et al. Pediatric Blood and Cancer. 2019; 66.

TNF-mediated compensatory immunity to mycobacterium avium in the absence of macrophage activation by IFN-γ. Resende, M; Cardoso, MS; Frois-Martins, R; Borges, M; Jordan, MB; Castro, AG; Appelberg, R. Journal of immunology (Baltimore, Md. : 1950). 2019; 203:2451-2458.